22 mar: Novo Nordisk/Deutsche: Sænker anbefaling til "sælg"
22 mar: ECB kan droppe krisefond på 40 mia. euro - avis
22-03-2012 08:20:51

Dräger buys back 41.1 percent of participation certificates

Drägerwerk AG & Co. KGaA /

Dräger buys back 41.1 percent of participation certificates

. Processed and transmitted by Thomson Reuters ONE.

The issuer is solely responsible for the content of this announcement.

Lübeck - Drägerwerk AG & Co. KGaA has bought back 41.1 percent of its issued participation certificates and now intends to redeem the purchased participation certificates. The participation certificates bought back have a total purchase price of EUR 122.1 million. This transaction decreases the equity ratio by about three percentage points; earnings per share on imputed actual full distribution will improve by 19 percent (based on the consolidated group financial statement 2011).

Improved capital structure

"Thanks to the successful buy-back, we have come a great deal closer to our goal of improving our capital structure. As such, we would like to thank all participation certificate holders that have accepted our offer," says Stefan Dräger, Chairman of the Executive Board of Drägerwerk Verwaltungs AG.

Premium for participation certificate holders was 26 percent

On February 15, 2012, Dräger requested that holders of participation certificate series A, K and D (series A: ISIN DE0005550651, WKN 555065; series K: ISIN DE0005550677, WKN 555067; series D: ISIN DE0005550719, WKN 555071) offer Dräger their participation certificates at a price of EUR 210 per share. The buy-back price named by Dräger corresponded to a premium of 26 percent on the average participation certificate price in the three months prior to the offer on February 15, 2012.

Disclaimer

This press release contains statements on the future development of Dräger Group. These forward-looking statements are based on the current expectations, presumptions, and forecasts of the Executive Board as well as the information available to it to date and have been prepared to the best of its knowledge and belief. No guarantee or liability for the occurrence of the future developments and results specified can be assumed in respect of such forward-looking statements. Rather, the future developments and results are dependent on a number of factors. They entail risks and uncertainties beyond the Company's control and are based on assumptions which could prove to be incorrect. Notwithstanding any legal requirements to adjust forecasts, Dräger does not assume any obligation to update the forward-looking statements contained in this report. Please go to Investor Relations / Financial Calendar at www.draeger.com for information on all important financial dates.

Contact

Corporate Communications:

Melanie Kamann

Tel. +49 451 882-3998

melanie.kamann@draeger.com

Investor Relations:

Vanina Hoffmann

Tel. +49 451 882-2685

vanina.hoffmann@draeger.com

Drägerwerk AG & Co. KgaA

Moislinger Allee 53-55

23542 Lübeck, Germany

www.draeger.com

Press release (PDF)


This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the

information contained therein.

Source: Drägerwerk AG & Co. KGaA via Thomson Reuters ONE

HUG#1596398

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
24 jul
 
Først så tager skattevæsenet  halvdelen af din indkomst.  - Så tager banken 200 kr i kurtage (Udenla..
38
27 jul
 
  Indledning Over sommeren har jeg læst adskillige bøger om aktier og investering, som har givet mig..
30
27 jul
 
Tese Toneangivende vestlige lande er på vej i fuld fart i retning mod ekspansiv finanspolitik. Dette..
28
24 jul
 
Til gengæld er operation ved sygdom gratis....Hvis du overlever ventetiden.   Til gengæld kan du som..
28
28 jul
 
Det er nu to døgn + ca. 3 timer siden du sidst oprettede en tråd, stillede det samme spørgsmål vedr...
16
27 jul
VELO
Og flyt så - for en tid - fokus hen på "ejerne" af Veloxis Pharmaceuticals. Især den ene - NOVO A/S ..
15
28 jul
GEN
På mange måder ligger Genmab lige nu (kort sigt) i et "alting kan ske" område. Overordnet set ligger..
14
24 jul
 
ER DET IKKE FEDT AT BO I ET LAND SOM DANMARK, uanset hvor meget I brokker jer over det ene eller and..
14
28 jul
FING-B
Når man ikke tænker i analyser: Deværre tror jeg ikke, at kursen for FPC bliver stabil, så længe der..
13
24 jul
 
Jeg kender et par stykker som er flyttet til USA (og også et par stykker i Tyskland). Deres rådighed..
13

Analytikere: Maersk Line kan stå foran katastrofalt regnskab

29-07-2016 16:20:51
Lave priser og for mange skibe på havene er en hovedpine for rederiet Maersk Line, der formentlig står over for et underskud, når A.P. Møller-Mærsk kommer med r..

Carlsberg/Sydbank: AB Inbev-regnskab er ikke problematisk - NY

29-07-2016 13:54:07
(tilføjet info om fusionen med Sabmiller og lavet mindre justeringer, red.)Der er blandede signaler i regnskabet fra AB Inbev, når det kommer til de markeder, h..

Aktier/middag: Jyske Bank til tops forud for stresstest

29-07-2016 11:38:56
Finansaktierne har vind i sejlene fredag middag, hvor markedet afventer en tilsynsvurdering af status for de største europæiske banker.Det danske aktiemarked li..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Analytikere: Maersk Line kan stå foran katastrofalt regnskab
2
Fredagens aktier: C20 lagde brexit-tab bag sig i juli
3
Sabmiller: Bestyrelse anbefaler købstilbud fra AB Inbev
4
USA: Michigan-indekset stort set som ventet

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2016  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
30. juli 2016 15:01:08
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20160728.2 - EUROWEB7 - 2016-07-30 15:01:08 - 2016-07-30 15:01:08 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x